-
1
-
-
0030799090
-
Activating mutations for the met tyrosine kinase receptor in human cancer
-
[Research Support, U.S. Gov't, P.H.S.]
-
M. Jeffers, L. Schmidt, N. Nakaigawa, C.P. Webb, G. Weirich, and T. Kishida et al. Activating mutations for the met tyrosine kinase receptor in human cancer Proc. Natl. Acad. Sci. U.S.A. 94 Oct 14, 21 1997 11445 11450 [Research Support, U.S. Gov't, P.H.S.]
-
(1997)
Proc. Natl. Acad. Sci. U.S.A.
, vol.94
, Issue.OCT 14 21
, pp. 11445-11450
-
-
Jeffers, M.1
Schmidt, L.2
Nakaigawa, N.3
Webb, C.P.4
Weirich, G.5
Kishida, T.6
-
2
-
-
17344381429
-
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
-
[Research Support, Non-U.S. Gov't]
-
L. Schmidt, F.M. Duh, F. Chen, T. Kishida, G. Glenn, and P. Choyke et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas Nat. Genet. 16 May, 1 1997 68 73 [Research Support, Non-U.S. Gov't]
-
(1997)
Nat. Genet.
, vol.16
, Issue.MAY 1
, pp. 68-73
-
-
Schmidt, L.1
Duh, F.M.2
Chen, F.3
Kishida, T.4
Glenn, G.5
Choyke, P.6
-
3
-
-
33847260150
-
Tyrosine kinase mutations in human cancer
-
E. Lengyel, K. Sawada, and R. Salgia Tyrosine kinase mutations in human cancer Curr Mol Med. 7 1 2007 77 84
-
(2007)
Curr Mol Med.
, vol.7
, Issue.1
, pp. 77-84
-
-
Lengyel, E.1
Sawada, K.2
Salgia, R.3
-
4
-
-
0029809118
-
Branching tubulogenesis but not scatter of madin-darby canine kidney cells requires a functional Grb2 binding site in the Met receptor tyrosine kinase
-
[Research Support, Non-U.S. Gov't]
-
T.M. Fournier, D. Kamikura, K. Teng, and M. Park Branching tubulogenesis but not scatter of madin-darby canine kidney cells requires a functional Grb2 binding site in the Met receptor tyrosine kinase J. Biol. Chem. 271 Sep 6, 36 1996 22211 22217 [Research Support, Non-U.S. Gov't]
-
(1996)
J. Biol. Chem.
, vol.271
, Issue.SEP 6 36
, pp. 22211-22217
-
-
Fournier, T.M.1
Kamikura, D.2
Teng, K.3
Park, M.4
-
5
-
-
0035930341
-
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein
-
[Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]
-
P. Peschard, T.M. Fournier, L. Lamorte, M.A. Naujokas, H. Band, and W.Y. Langdon et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein Mol. Cell. 8 Nov, 5 2001 995 1004 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]
-
(2001)
Mol. Cell.
, vol.8
, Issue.NOV 5
, pp. 995-1004
-
-
Peschard, P.1
Fournier, T.M.2
Lamorte, L.3
Naujokas, M.A.4
Band, H.5
Langdon, W.Y.6
-
6
-
-
0035473477
-
Beyond the RING: CBL proteins as multivalent adapters
-
[Research Support, U.S. Gov't, P.H.S. Review]
-
A.Y. Tsygankov, A.M. Teckchandani, E.A. Feshchenko, and G. Swaminathan Beyond the RING: CBL proteins as multivalent adapters Oncogene 20 Oct 1, 44 2001 6382 6402 [Research Support, U.S. Gov't, P.H.S. Review]
-
(2001)
Oncogene
, vol.20
, Issue.OCT 1 44
, pp. 6382-6402
-
-
Tsygankov, A.Y.1
Teckchandani, A.M.2
Feshchenko, E.A.3
Swaminathan, G.4
-
7
-
-
27144512084
-
Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation
-
[Research Support, Non-U.S. Gov't]
-
J.V. Abella, P. Peschard, M.A. Naujokas, T. Lin, C. Saucier, and S. Urbe et al. Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation Mol. Cell. Biol. 25 Nov, 21 2005 9632 9645 [Research Support, Non-U.S. Gov't]
-
(2005)
Mol. Cell. Biol.
, vol.25
, Issue.NOV 21
, pp. 9632-9645
-
-
Abella, J.V.1
Peschard, P.2
Naujokas, M.A.3
Lin, T.4
Saucier, C.5
Urbe, S.6
-
8
-
-
0035901973
-
Down-regulation of MET, the receptor for hepatocyte growth factor
-
[Research Support, Non-U.S. Gov't]
-
D.E. Hammond, S. Urbe, G.F. Vande Woude, and M.J. Clague Down-regulation of MET, the receptor for hepatocyte growth factor Oncogene 20 May 17, 22 2001 2761 2770 [Research Support, Non-U.S. Gov't]
-
(2001)
Oncogene
, vol.20
, Issue.MAY 17 22
, pp. 2761-2770
-
-
Hammond, D.E.1
Urbe, S.2
Vande Woude, G.F.3
Clague, M.J.4
-
9
-
-
36049051915
-
Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway
-
[Research Support, Non-U.S. Gov't]
-
H.H. Mak, P. Peschard, T. Lin, M.A. Naujokas, D. Zuo, and M. Park Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway Oncogene 26 Nov 8, 51 2007 7213 7221 [Research Support, Non-U.S. Gov't]
-
(2007)
Oncogene
, vol.26
, Issue.NOV 8 51
, pp. 7213-7221
-
-
Mak, H.H.1
Peschard, P.2
Lin, T.3
Naujokas, M.A.4
Zuo, D.5
Park, M.6
-
10
-
-
61549138135
-
Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers
-
[Research Support, Non-U.S. Gov't]
-
R. Onozato, T. Kosaka, H. Kuwano, Y. Sekido, Y. Yatabe, and T. Mitsudomi Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers J. Thorac. Oncol. 4 Jan, 1 2009 5 11 [Research Support, Non-U.S. Gov't]
-
(2009)
J. Thorac. Oncol.
, vol.4
, Issue.JAN 1
, pp. 5-11
-
-
Onozato, R.1
Kosaka, T.2
Kuwano, H.3
Sekido, Y.4
Yatabe, Y.5
Mitsudomi, T.6
-
11
-
-
31544462584
-
Somatic mutations lead to an oncogenic deletion of met in lung cancer
-
M. Kong-Beltran, S. Seshagiri, J. Zha, W. Zhu, K. Bhawe, and N. Mendoza et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer Cancer Res. 66 Jan 1, 1 2006 283 289
-
(2006)
Cancer Res.
, vol.66
, Issue.JAN 1 1
, pp. 283-289
-
-
Kong-Beltran, M.1
Seshagiri, S.2
Zha, J.3
Zhu, W.4
Bhawe, K.5
Mendoza, N.6
-
12
-
-
13944276728
-
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer
-
[Research Support, Non-U.S. Gov't]
-
P.C. Ma, R. Jagadeeswaran, S. Jagadeesh, M.S. Tretiakova, V. Nallasura, and E.A. Fox et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer Cancer Res. 65 Feb 15, 4 2005 1479 1488 [Research Support, Non-U.S. Gov't]
-
(2005)
Cancer Res.
, vol.65
, Issue.FEB 15 4
, pp. 1479-1488
-
-
Ma, P.C.1
Jagadeeswaran, R.2
Jagadeesh, S.3
Tretiakova, M.S.4
Nallasura, V.5
Fox, E.A.6
-
13
-
-
77950859967
-
Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion
-
Y. Asaoka, M. Tada, T. Ikenoue, M. Seto, M. Imai, and K. Miyabayashi et al. Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion Biochem. Biophys. Res. Commun. 394 Apr 16, 4 2010 1042 1046
-
(2010)
Biochem. Biophys. Res. Commun.
, vol.394
, Issue.APR 16 4
, pp. 1042-1046
-
-
Asaoka, Y.1
Tada, M.2
Ikenoue, T.3
Seto, M.4
Imai, M.5
Miyabayashi, K.6
-
14
-
-
79959999334
-
A direct role for Met endocytosis in tumorigenesis
-
C. Joffre, R. Barrow, L. Menard, V. Calleja, I.R. Hart, and S. Kermorgant A direct role for Met endocytosis in tumorigenesis Nat. Cell. Biol. 13 Jul, 7 2011 827 837
-
(2011)
Nat. Cell. Biol.
, vol.13
, Issue.JUL 7
, pp. 827-837
-
-
Joffre, C.1
Barrow, R.2
Menard, L.3
Calleja, V.4
Hart, I.R.5
Kermorgant, S.6
-
15
-
-
0029850677
-
Rab11 regulates recycling through the pericentriolar recycling endosome
-
[Research Support, Non-U.S. Gov't]
-
O. Ullrich, S. Reinsch, S. Urbe, M. Zerial, and R.G. Parton Rab11 regulates recycling through the pericentriolar recycling endosome J. Cell. Biol. 135 Nov, 4 1996 913 924 [Research Support, Non-U.S. Gov't]
-
(1996)
J. Cell. Biol.
, vol.135
, Issue.NOV 4
, pp. 913-924
-
-
Ullrich, O.1
Reinsch, S.2
Urbe, S.3
Zerial, M.4
Parton, R.G.5
-
16
-
-
84896740344
-
A Study of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor
-
NCT00585195. [cited 2013 31.07.2013]
-
A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer. NCT00585195. [cited 2013 31.07.2013]; Available from: http://www.clinicaltrials.gov/ct2/show/NCT00585195? term=NCT00585195&rank=1.
-
Patients with Advanced Cancer
-
-
-
18
-
-
84858341589
-
MET signaling: Novel targeted inhibition and its clinical development in lung cancer
-
[Review]
-
Y. Feng, P.S. Thiagarajan, and P.C. Ma MET signaling: novel targeted inhibition and its clinical development in lung cancer J. Thorac. Oncol. 7 Feb, 2 2012 459 467 [Review]
-
(2012)
J. Thorac. Oncol.
, vol.7
, Issue.FEB 2
, pp. 459-467
-
-
Feng, Y.1
Thiagarajan, P.S.2
Ma, P.C.3
-
19
-
-
84856020870
-
Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma
-
[Research Support, Non-U.S. Gov't Review]
-
J. Gao, Y. Inagaki, P. Song, X. Qu, N. Kokudo, and W. Tang Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma Pharmacol. Res. 65 Jan, 1 2012 23 30 [Research Support, Non-U.S. Gov't Review]
-
(2012)
Pharmacol. Res.
, vol.65
, Issue.JAN 1
, pp. 23-30
-
-
Gao, J.1
Inagaki, Y.2
Song, P.3
Qu, X.4
Kokudo, N.5
Tang, W.6
-
20
-
-
84856152266
-
Targeting MET in cancer: Rationale and progress
-
[Research Support, Non-U.S. Gov't Review]
-
E. Gherardi, W. Birchmeier, C. Birchmeier, and G. Vande Woude Targeting MET in cancer: rationale and progress Nat. Rev. Cancer 12 Feb, 2 2012 89 103 [Research Support, Non-U.S. Gov't Review]
-
(2012)
Nat. Rev. Cancer
, vol.12
, Issue.FEB 2
, pp. 89-103
-
-
Gherardi, E.1
Birchmeier, W.2
Birchmeier, C.3
Vande Woude, G.4
-
22
-
-
3142691273
-
The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants
-
[Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]
-
S. Berthou, D.M. Aebersold, L.S. Schmidt, D. Stroka, C. Heigl, and B. Streit et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants Oncogene 23 Jul 8, 31 2004 5387 5393 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]
-
(2004)
Oncogene
, vol.23
, Issue.JUL 8 31
, pp. 5387-5393
-
-
Berthou, S.1
Aebersold, D.M.2
Schmidt, L.S.3
Stroka, D.4
Heigl, C.5
Streit, B.6
-
23
-
-
76849098324
-
Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274
-
[Research Support, Non-U.S. Gov't]
-
Y. Zimmer, A.V. Vaseva, M. Medová, B. Streit, W. Blank-Liss, and R.H. Greiner et al. Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274 Cancer Lett. 289 Mar 28, 2 2010 228 236 [Research Support, Non-U.S. Gov't]
-
(2010)
Cancer Lett.
, vol.289
, Issue.MAR 28 2
, pp. 228-236
-
-
Zimmer, Y.1
Vaseva, A.V.2
Medová, M.3
Streit, B.4
Blank-Liss, W.5
Greiner, R.H.6
-
24
-
-
0141481285
-
A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase
-
[Research Support, Non-U.S. Gov't]
-
M. Sattler, Y.B. Pride, P. Ma, J.L. Gramlich, S.C. Chu, and L.A. Quinnan et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase Cancer Res. 63 Sep 1, 17 2003 5462 5469 [Research Support, Non-U.S. Gov't]
-
(2003)
Cancer Res.
, vol.63
, Issue.SEP 1 17
, pp. 5462-5469
-
-
Sattler, M.1
Pride, Y.B.2
Ma, P.3
Gramlich, J.L.4
Chu, S.C.5
Quinnan, L.A.6
-
25
-
-
84879001675
-
EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors
-
[Research Support, Non-U.S. Gov't]
-
F. Bladt, B. Faden, M. Friese-Hamim, C. Knuehl, C. Wilm, and C. Fittschen et al. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors Clin. Cancer Res. 19 Jun 1, 11 2013 2941 2951 [Research Support, Non-U.S. Gov't]
-
(2013)
Clin. Cancer Res.
, vol.19
, Issue.JUN 1 11
, pp. 2941-2951
-
-
Bladt, F.1
Faden, B.2
Friese-Hamim, M.3
Knuehl, C.4
Wilm, C.5
Fittschen, C.6
-
26
-
-
84887499021
-
The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants
-
M. Medová, B. Pochon, B. Streit, W. Blank-Liss, P. Francica, and D. Stroka et al. The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants Mol. Cancer Ther. 12 Nov, 11 2013 2415 2424
-
(2013)
Mol. Cancer Ther.
, vol.12
, Issue.NOV 11
, pp. 2415-2424
-
-
Medová, M.1
Pochon, B.2
Streit, B.3
Blank-Liss, W.4
Francica, P.5
Stroka, D.6
-
27
-
-
0030839876
-
Efficient cellular transformation by the Met oncoprotein requires a functional Grb2 binding site and correlates with phosphorylation of the Grb2-associated proteins, Cbl and Gab1
-
[Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]
-
E.D. Fixman, M. Holgado-Madruga, L. Nguyen, D.M. Kamikura, T.M. Fournier, and A.J. Wong et al. Efficient cellular transformation by the Met oncoprotein requires a functional Grb2 binding site and correlates with phosphorylation of the Grb2-associated proteins, Cbl and Gab1 J. Biol. Chem. 272 Aug 8, 32 1997 20167 20172 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]
-
(1997)
J. Biol. Chem.
, vol.272
, Issue.AUG 8 32
, pp. 20167-20172
-
-
Fixman, E.D.1
Holgado-Madruga, M.2
Nguyen, L.3
Kamikura, D.M.4
Fournier, T.M.5
Wong, A.J.6
-
28
-
-
0037075606
-
The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met
-
[Research Support, Non-U.S. Gov't]
-
A. Petrelli, G.F. Gilestro, S. Lanzardo, P.M. Comoglio, N. Migone, and S. Giordano The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met Nature 416 Mar 14, 6877 2002 187 190 [Research Support, Non-U.S. Gov't]
-
(2002)
Nature
, vol.416
, Issue.MAR 14 6877
, pp. 187-190
-
-
Petrelli, A.1
Gilestro, G.F.2
Lanzardo, S.3
Comoglio, P.M.4
Migone, N.5
Giordano, S.6
-
29
-
-
84861733799
-
MET: A promising anticancer therapeutic target
-
[Review]
-
S. Peters, and A.A. Adjei MET: a promising anticancer therapeutic target Nat. Rev. Clin. Oncol. 9 Jun, 6 2012 314 326 [Review]
-
(2012)
Nat. Rev. Clin. Oncol.
, vol.9
, Issue.JUN 6
, pp. 314-326
-
-
Peters, S.1
Adjei, A.A.2
-
30
-
-
48649092035
-
Coupling of mutated Met variants to DNA repair via Abl and Rad51
-
S.S. Ganapathipillai, M. Medová, D.M. Aebersold, P.W. Manley, S. Berthou, and B. Streit et al. Coupling of mutated Met variants to DNA repair via Abl and Rad51 Cancer Res. 68 Jul, 15, 14 2008 5769 5777
-
(2008)
Cancer Res.
, vol.68
, Issue.JUL 15 14
, pp. 5769-5777
-
-
Ganapathipillai, S.S.1
Medová, M.2
Aebersold, D.M.3
Manley, P.W.4
Berthou, S.5
Streit, B.6
-
31
-
-
84891319812
-
The Molecular crosstalk between the MET receptor tyrosine kinase and the DNA damage response-biological and clinical aspects
-
Dec (19, 1)
-
M. Medová, D.M. Aebersold, and Y. Zimmer The Molecular crosstalk between the MET receptor tyrosine kinase and the DNA damage response-biological and clinical aspects Cancers (Basel) 6 2013 1 27 Dec (19, 1)
-
(2013)
Cancers (Basel)
, vol.6
, pp. 1-27
-
-
Medová, M.1
Aebersold, D.M.2
Zimmer, Y.3
-
32
-
-
0033392493
-
Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1
-
[Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]
-
G. Levkowitz, H. Waterman, S.A. Ettenberg, M. Katz, A.Y. Tsygankov, and I. Alroy et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1 Mol. Cell. 4 Dec, 6 1999 1029 1040 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]
-
(1999)
Mol. Cell.
, vol.4
, Issue.DEC. 6
, pp. 1029-1040
-
-
Levkowitz, G.1
Waterman, H.2
Ettenberg, S.A.3
Katz, M.4
Tsygankov, A.Y.5
Alroy, I.6
|